Dogwood Therapeutics Announces Patient Dosing in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy Induced Neuropathy (CINP) to Commence First Quarter of 2025 Jan 21, 2025 09:15AM
Dogwood Therapeutics (DWTX) Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study Nov 18, 2024 08:46AM
Dogwood Therapeutics, Inc. Announces Low Dose IMC-2 Treatment Reduces Long-COVID Related Fatigue and Sleep Disturbance in an Investigator-Initiated Study Nov 18, 2024 08:45AM
Dogwood Therapeutics Announces Third Quarter 2024 Financial Results Nov 7, 2024 07:05AM
Dogwood Therapeutics to Report Third Quarter 2024 Financial Results and Provide Corporate Update on Thursday, November 7, 2024 Oct 31, 2024 09:15AM
View Older Stories

Oct 30, 2024 09:15AM Dogwood Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Aug 8, 2024 09:15AM Virios Therapeutics Announces Second Quarter 2024 Financial Results
Aug 1, 2024 09:41AM Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
Jul 23, 2024 09:15AM Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center
May 9, 2024 07:45AM Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update
May 2, 2024 09:15AM Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
Mar 26, 2024 09:16AM Virios Therapeutics (VIRI) Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
Mar 26, 2024 09:15AM Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID
Feb 29, 2024 09:15AM Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results
Feb 28, 2024 09:16AM Virios Therapeutics (VIRI) Issues Shareholder Letter
Feb 28, 2024 09:15AM Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones
Jan 22, 2024 09:00AM Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID
Jan 2, 2024 07:05AM Virios Therapeutics (VIRI) Reaches Alignment with FDA on Requirements for Advancing IMC-2 for Long-COVID
Jan 2, 2024 07:05AM Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID
Nov 13, 2023 07:05AM Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update
Nov 6, 2023 07:05AM Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023
Oct 12, 2023 07:05AM Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023
Sep 18, 2023 07:05AM Virios Therapeutics (VIRI) Announces Termination of At-The-Market Sales Agreement
Sep 18, 2023 07:05AM Virios Therapeutics Announces Termination of At-The-Market Sales Agreement
Sep 12, 2023 07:05AM Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023
Aug 14, 2023 07:21AM Virios Therapeutics (VIRI) Halts At-The-Market Offering Sales
Aug 14, 2023 07:05AM Virios Therapeutics Announces Halt to At-The-Market Offering Sales
Aug 10, 2023 07:05AM Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update
Aug 9, 2023 07:06AM Virios Therapeutics (VIRI) to Advance IMC-1 to Phase 3 Development
Aug 9, 2023 07:05AM Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia
Aug 3, 2023 04:05PM Virios Therapeutics to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
Jul 17, 2023 07:05AM Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Labe
May 25, 2023 04:05PM Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 15, 2023 07:05AM Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia
May 11, 2023 07:05AM Virios Therapeutics Announces First Quarter 2023 Financial Results
May 4, 2023 07:05AM Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023
Apr 24, 2023 04:15PM Virios Therapeutics (VIRI) Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program
Apr 24, 2023 04:15PM Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia
Mar 14, 2023 07:05AM Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results
Mar 7, 2023 07:05AM Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023
Feb 13, 2023 07:05AM Virios Therapeutics (VIRI) Announces Exploratory Long-COVID Trial Top-Line Data Projected in June 2023
Feb 13, 2023 07:05AM Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023
Jan 5, 2023 07:04AM Virios Therapeutics (VIRI) Scheduled FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program
Jan 5, 2023 07:00AM Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program
Nov 29, 2022 07:05AM Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase
Nov 14, 2022 07:05AM Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update
Nov 3, 2022 07:05AM Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022
Sep 19, 2022 07:15AM Virios Therapeutics (VIRI) Phase 2b Study of IMC-1 in Fibromyalgia Did Not Achieve Statistical Significance
Sep 19, 2022 07:05AM Virios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in Fibromyalgia
Aug 15, 2022 07:05AM Virios Therapeutics’ Announces Dosing of First Patient in IMC-2 Long-COVID Treatment Trial
Aug 11, 2022 07:05AM Virios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
Aug 10, 2022 04:01PM Virios Therapeutics, Inc. to Present at Investor Summit Group’s Q3 Virtual Conference
Aug 4, 2022 07:05AM Virios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022
Jun 1, 2022 07:05AM Virios Therapeutics (VIRI) Featured in Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders
Jun 1, 2022 07:05AM Virios Therapeutics’ Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patien
View Older Stories